S.Amdt. 2442Senate118th Congress (2023-2025)

S.Amdt. 2442

Submitted July 11, 2024

Legislative Activity

Stay on top of the latest movement without scrolling through every action

Floor Latest Action

Senate amendment submitted

July 11, 2024

Text

Submitted

SA 2442. Mr. RUBIO submitted an amendment intended to be proposed by
him to the bill S. 4638, to authorize appropriations for fiscal year
2025 for military activities of the Department of Defense, for military
construction, and for defense activities of the Department of Energy,
to prescribe military personnel strengths for such fiscal year, and for
other purposes; which was ordered to lie on the table; as follows:

At the end of subtitle H of title X, insert the following:

SEC. 1095. REVIEW OF DOMESTIC BIOPHARMACEUTICAL MANUFACTURING
CAPABILITIES.

(a) In General.--The Secretary of Health and Human Services
(referred to in this section as the ``Secretary''), in
cooperation with the Director of the Biomedical Advanced
Research and Development Authority, shall seek to enter into
an agreement with the National Institute for Innovation in
Manufacturing Biopharmaceuticals to perform the services
described in subsection (b).
(b) Review and Recommendations.--Under an agreement
described in subsection (a) between the Secretary, the
Director of the Biomedical Advanced Research and Development
Authority, and the National Institute for Innovation in
Manufacturing Biopharmaceuticals, the National Institute for
Innovation in Manufacturing Biopharmaceuticals shall--
(1) review current domestic biopharmaceutical manufacturing
capacity at the Department of Health and Human Services and
such department's adaptability to various threats;
(2) draft recommendations for developing, demonstrating,
deploying, and advancing new domestic biopharmaceutical
manufacturing technologies that address gaps identified under
paragraph (1) and align Federal technologies with
technologies available to the private sector, including
through the new BioMAP initiative of the Biomedical Advanced
Research and Development Authority; and
(3) identify other opportunities and priorities to improve
the United States public health and medical preparedness and
response capabilities and domestic biopharmaceutical
manufacturing capabilities.
______